{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:25:57Z","timestamp":1793913957332,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.020","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:05:58Z","timestamp":1792080358000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-1253","authenticated-orcid":false,"given":"Natalia","family":"Tijaro Ovalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-142X","authenticated-orcid":false,"given":"Andrew","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwamber","family":"Talla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Lutrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-7880","authenticated-orcid":false,"given":"Richard","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Samorodnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.10.020_bib0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.blre.2018.11.001","article-title":"Allogeneic hematopoietic cell transplantation; the current renaissance","volume":"34","author":"Copelan","year":"2019","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.020_bib0002","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.020_bib0003","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbmt.2011.01.005","article-title":"T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies","volume":"17","author":"Jakubowski","year":"2011","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.020_bib0004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/bmt.2014.302","article-title":"Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts","volume":"50","author":"Hobbs","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.020_bib0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bbmt.2016.12.633","volume":"23","author":"Barba","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.020_bib0006","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bbmt.2018.01.001","article-title":"Allogeneic stem cell transplantation for advanced myelodysplastic syndrome: comparison of outcomes between CD34+ selected and unmodified hematopoietic stem cell transplantation","volume":"24","author":"Tamari","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.020_bib0007","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2017.07.012","article-title":"The impact of toxicities on first-year outcomes after ex vivo CD34+-selected allogeneic hematopoietic cell transplantation in adults with hematologic malignancies","volume":"23","author":"Kosuri","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.020_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbmt.2017.08.033","article-title":"Effects of late toxicities on outcomes in long-term survivors of ex-vivo CD34+-selected allogeneic hematopoietic cell transplantation","volume":"24","author":"Scordo","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.020_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbmt.2017.08.040","article-title":"Impact of toxicity on survival for older adult patients after CD34+ selected allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.020_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of Calcineurin inhibitor\u2013free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.10.020_bib0011","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.bbmt.2019.02.021","article-title":"Standard antithymocyte globulin dosing results in poorer outcomes in overexposed patients after ex vivo CD34+ selected allogeneic hematopoietic cell transplantation","volume":"25","author":"Scordo","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.020_bib0012","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/bloodadvances.2021005584","article-title":"Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation","volume":"6","author":"Lakkaraja","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.020_bib0013","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1016\/S2352-3026(25)00293-5","article-title":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study","volume":"12","author":"Scordo","year":"2025","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.020_bib0014","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bbmt.2015.07.010","article-title":"CD34-Selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse","volume":"21","author":"Tamari","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.020_bib0015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41409-018-0195-4","article-title":"Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen","volume":"53","author":"Sweiss","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.020_bib0016","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/em.20603","article-title":"Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies","volume":"51","author":"Valdez","year":"2010","journal-title":"Environ Mol Mutagen"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.020_bib0017","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bcp.2010.09.027","article-title":"The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling","volume":"81","author":"Valdez","year":"2011","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.020_bib0018","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbmt.2015.08.025","article-title":"CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma","volume":"22","author":"Smith","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.020_bib0019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbmt.2019.08.023","article-title":"Presalvage international staging system stage and other important outcome associations in CD34+-selected allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"26","author":"Bryant","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.jtct.2026.10.020_bib0020","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1182\/bloodadvances.2023009708","article-title":"Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.020_bib0021","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.020_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcyt.2020.05.005","article-title":"Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation","volume":"22","author":"van Roessel","year":"2020","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.020_bib0023","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.jtct.2024.02.008","article-title":"Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in pediatric and adult patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)","volume":"30","author":"Scordo","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.020_bib0024","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.020_bib0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.020_bib0026","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.020_bib0027","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.10.020_bib0028","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy \u2013 a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.020_bib0029","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.020_bib0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.020_bib0031","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.020_bib0032","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S2352-3026(18)30156-X","article-title":"Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial","volume":"5","author":"Popat","year":"2018","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.020_bib0033","doi-asserted-by":"crossref","first-page":"913.e1","DOI":"10.1016\/j.jtct.2021.07.021","article-title":"Myeloablative fractionated busulfan with fludarabine in older patients: long term disease-specific outcomes of a prospective phase II clinical trial","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"10.1016\/j.jtct.2026.10.020_bib0034","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1182\/bloodadvances.2023010850","article-title":"Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities","volume":"7","author":"Popat","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jtct.2026.10.020_bib0035","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/bloodadvances.2023010310","article-title":"Tacrolimus\/methotrexate vs tacrolimus\/reduced-dose methotrexate\/mycophenolate for graft-versus-host disease prevention","volume":"7","author":"Hamilton","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.020_bib0036","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtct.2022.05.012","article-title":"A clinical review of the different strategies to minimize hemorrhagic cystitis associated with the use of post-transplantation cyclophosphamide in an allogeneic transplant","volume":"28","author":"Ngo","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.020_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1402106","article-title":"Allogeneic stem cell transplantation in multiple myeloma: is there still a place?","volume":"14","author":"Liberatore","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.020_bib0038","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:50:29Z","timestamp":1793911829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S2666636726008092"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}